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Private speciﬁcities of CD8 T cell responses 
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CD8 T cell cross-reactivity between viruses can play roles in protective heterologous 
immunity and damaging immunopathology. This cross-reactivity is sometimes predictable, 
such as between lymphocytic choriomeningitis virus (LCMV) and Pichinde virus, where cross-
reactive epitopes share six out of eight amino acids. Here, however, we demonstrate more 
subtle and less predictable cross-reactivity between LCMV and the unrelated vaccinia virus 
(VV). Epitope-specific T cell receptor usage differed between individual LCMV-infected 
C57BL/6 mice, even though the mice had similar epitope-specific T cell hierarchies. LCMV-
immune mice challenged with VV showed variations, albeit in a distinct hierarchy, in 
proliferative expansions of and down-regulation of IL-7R
 
 
 
 by T cells specific to different 
LCMV epitopes. T cell responses to a VV-encoded epitope that is cross-reactive with LCMV 
fluctuated greatly in VV-infected LCMV-immune mice. Adoptive transfers of splenocytes 
from individual LCMV-immune donors resulted in nearly identical VV-induced responses in 
each of several recipients, but responses differed depending on the donor. This indicates that 
the specificities of T cell responses that are not shared between individuals may influence 
cross-reactivity with other antigens and play roles in heterologous immunity upon encounter 
with another pathogen. This variability in cross-reactive T cell expansion that is unique to 
the individual may underlie variation in the pathogenesis of infectious diseases.
 
Variations in the pathogenesis of viral infections
can sometimes be attributed to the infection
history of a host, where exposure to unrelated
pathogens may unexpectedly contribute either
to protective immunity or to enhanced immu-
nopathology (1). This heterologous immunity
has now been demonstrated in several murine
models of infection, where T cells specific to
previously encountered viruses participate in
the immune response to viruses subsequently
encountered (2–4). Recent work showing hu-
man T cell cross-reactivity between influenza
virus and hepatitis C virus (5), between influenza
virus and Epstein-Barr virus (6), between human
papilloma virus and coronavirus (7), and be-
tween different strains of dengue virus (8) argues
that similar issues of heterologous immunity
should be examined in human infections.
Mouse models have shown that a history
of a heterologous virus infection can alter the
kinetics and the hierarchy of T cells responding
to peptide epitopes encoded by the infecting
virus, and this skewing of T cell responsiveness
may be either beneficial or harmful to the host
(2, 6). Any foreign protein is likely to have sev-
eral amino acid epitope sequences with appro-
priate motifs to engage a given MHC mol-
ecule, but the T cell response to a virus
infection is usually focused against a narrow
subset of these potential epitopes. This is a
consequence of T cell immunodominance,
which is a very fickle phenomenon. If immuno-
dominant epitopes are experimentally deleted
from a pathogen, other epitopes almost invari-
ably emerge to dominate the response (9).
This is either because they become presented
better at the MHC level or because they stim-
ulate T cells whose initial frequencies were lower
than the originally immunodominant ones (9).
T cell immunodominance can be dramatically
affected by a prior infection with a pathogen
that encodes an epitope that generates T cells
that cross-react with a second pathogen (2).
For example, lymphocytic choriomeningitis
virus (LCMV) and Pichinde virus (PV) each
encode weak subdominant epitopes with six
out of eight amino acids in common. Some T
cells can cross-react between those epitopes,
and when a host immune to one of those viruses
is infected with the other, this weak epitope
now dominates the T cell response, and the
normally dominant epitopes generate much
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weaker responses. The higher frequencies of memory T cells
specific to this cross-reactive epitope as compared with naive
T cells specific to the normally dominant epitopes gives an
advantage for proliferative expansion. Similarly, individuals
immune to one dengue virus serotype on infection with a
second serotype tend to generate T cell responses that better
recognize the first serotype, presumably because they were
expanded from the memory pool (8). It is noteworthy that
this deviation in T cell responses during dengue infections is
associated with serious pathological complications.
Under conditions of heterologous immunity, T cell re-
sponses are sometimes uniformly directed against strongly
cross-reactive epitopes, such as between LCMV and PV.
However, in other cases, patterns of heterologous immunity
and T cell cross-reactivity may be variable, such as between
LCMV and vaccinia virus (VV). A history of an LCMV in-
fection protects mice against VV, reducing VV titers 10–
100-fold by day 3 after infection, and dramatically changing
the T cell–dependent immunopathology (1, 3). Adoptive
transfer studies indicated that LCMV-immune CD4 and
CD8 T cells provided heterologous immunity in this system
(1). Ironically, a history of a VV infection has little effect on
immunity to LCMV (1). VV induces the proliferation of
some LCMV-specific memory T cells, but LCMV does not
induce detectable proliferation of VV-specific memory T
cells (4). A possible explanation to this enigma is that VV is a
virus that encodes 
 
 
 
200 proteins and perhaps 
 
 
 
1,000 T cell
epitopes with the capacity to trigger memory T cells present
at sufficient frequencies. In contrast, LCMV encodes only
four proteins. Thus, it seems that the many potential epi-
topes encoded by VV would more likely stimulate some
T cells in an LCMV-specific memory pool than would the
much more limited number of LCMV epitopes stimulating a
VV-immune pool.
However, protective immunity and the degree of immu-
nopathology varied between experiments, and our attempts
to define the epitope specificity of LCMV-specific T cells
reactivated by VV were complicated by poor reproducibility
in experiments. We have reported that VV frequently ex-
pands LCMV NP205-specific T cells from LCMV-immune
mice, but this was not always the case. In some mice, there
was expansion of T cells specific to other LCMV epitopes
(3, 4). This led us to question whether the specificities of
cross-reactive T cell responses under conditions of heterolo-
gous viral challenge may be unique to the individual.
Studies of the T cell receptor repertoire directed against
viral epitopes have revealed three principles. First, the reper-
toire is highly diverse, with sometimes hundreds of distinct
clones directed against a single epitope (10–12). Second,
epitope-specific responses between individuals are often
dominated by distinct V
 
 
 
 TCR usage and conserved amino
acid motifs in the TCR CDR3 region, which recognizes the
peptide-MHC (public specificities; references 11, 13, 14).
Third, genetically identical hosts nevertheless have distinct
epitope-specific T cell populations with different amino acid
sequences in the CDR3 regions (private specificities; refer-
ences 10, 15, 16). We questioned here whether “private”
determinants, which may not be very important for the rec-
ognition of the epitope initially driving that particular T cell,
may be important in a cross-reactive recognition of another
epitope. This would mean that some individuals experienc-
ing infections in sequence with two viruses may generate
cross-reactive responses between the viruses, whereas other
individuals with similar MHC would not. This variability
could presumably influence viral clearance and immunopa-
thology. Here, we show that the LCMV epitope-specific T
cell responses elicited by VV infection are indeed a function
of the unique T cell responses of an individual host. Some
common patterns are seen, but the private specificities of
LCMV-immune T cell populations drive this cross-reactive
antigen recognition.
 
RESULTS
Longitudinal analysis of LCMV-specific CD8 T cells upon 
heterologous PV or VV infection
 
LCMV infection of adult B6 mice generates a robust CD8 T
cell response, peaking at 8 or 9 d after infection and eventu-
ally establishing a stable virus-specific CD8 memory T cell
pool (17, 18), where 
 
 
 
20% of the CD8 T cells in the PBLs
can be identified as specific to LCMV-encoded epitopes
(Fig. 1, A and B). The hierarchy of responses against differ-
ent epitopes is very similar between immunologically naive
mice (Fig. 1 and reference 17), but the integrity of the
LCMV epitope-specific memory CD8 T cell pool is often
disrupted by heterologous viral infections, which preferen-
tially expand cross-reactive T cells while deleting noncross-
reactive ones (2, 19, 20). We have elaborated the impacts of
two heterologous viruses (PV and VV) on LCMV-immune
mice and found that these two viruses generated characteris-
tic and contrasting patterns of T cell responses to epitopes in
LCMV-immune mice (2–4). PV and LCMV share strongly
cross-reactive subdominant epitopes (PV-NP205 and LCMV-
NP205) that dominate the immune response when these vi-
ruses are infected in sequence (Fig. 1 A and reference 2). In
contrast, VV infection of LCMV-immune mice exhibits a
much less predictable pattern, where the specificity of ex-
panded T cells is not always the same between experiments
(Fig. 1 B and references 3, 4).
However, in most of our previous studies, we analyzed
the impacts of heterologous virus infections simply by com-
paring the LCMV-specific CD8 T cells between separate
groups of LCMV-immune control mice and LCMV-
immune mice infected with heterologous viruses. We ques-
tioned here whether individual mice could differ dramatically
in the patterns of their cross-reactivities to heterologous vi-
ruses and sought to compare epitope-specific responses after a
heterologous viral infection to the hierarchy of the T cell
repertoire in the LCMV-immune mouse before the heterol-
ogous viral challenge. To address these issues of immune re-
sponses unique to the individual, we adopted a longitudinal
analysis method to reiterate the impacts of heterologous PV
or VV infections on LCMV-immune mice. First, we exam- 
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Figure 1. Longitudinal analysis of LCMV-specific memory CD8 T 
cells on heterologous PV or VV infection. The frequency and the hier-
archy of LCMV-specific CD8 T cells in the peripheral blood of individual 
LCMV-immune mice were examined via IFN-  assay before (day 0) (A) PV 
or (B) VV infection and after the heterologous viral challenge (day 12). 
Plots show the LCMV epitope–induced IFN-  production from gated CD8 T 
cells costained with the activation/memory marker CD44 for better resolu-
tion. The percentages of epitope-specific CD8 T cells before and after virus 
infections were determined (top right quadrants) and the percent changes 
in those values are shown. The epitope-specific CD8 T cell percentages 
with a  1.5-fold increase are indicated with a bold outline box. Represen-
tative figures are shown for 3 out of 10 PV-infected and out of 26 VV-
infected LCMV-immune mice (Table I). (C) Alterations in the LCMV-specific 
CD8 T cell repertoire in the individual VV-infected LCMV-immune mice. 
The relative proportion of LCMV epitope–specific CD8 T cells (total per-
centage being 100%) in the individual LCMV-immune mice was compared 
before (white bar) and after (black bar) VV infections. *, epitope-specific 
CD8 T cells showing a  50% increase in their relative proportion upon VV 
infection. Representative data are shown for 6 out of 26 VV-infected 
LCMV-immune mice. (D) Time course of VV-induced LCMV-specific 
epitope response. Individual LCMV-immune mice were sequentially bled 
before and at days 4, 7, and 12 after VV challenge. This figure, showing a 
preferential response to NP205, is representative of similar experiments 
performed on 10 mice. 
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ined the frequency and the hierarchy of LCMV-specific CD8
T cells in the peripheral blood of individual LCMV-immune
mice before (day 0) PV or VV infection and then at late
stages of the heterologous viral challenge (Fig. 1, A and B,
day 12). A peptide epitope-induced intracellular IFN-
 
 
 
 assay
was used to identify and quantify epitope-specific T cells.
Analysis of individual LCMV-immune mice (day 0) re-
vealed some small variations in the magnitude of the T cell
response, but little variation in the epitope hierarchy (Fig. 1,
A and B). PV infection, as expected, induced a dramatic ex-
pansion of the strongly cross-reactive NP205-specific CD8
T cells in all of the PV-infected, LCMV-immune mice (Fig.
1 A). Concomitant with the expansion, there were signifi-
cant reductions in the frequencies of the rest of the non-
cross-reactive LCMV-specific CD8 T cells. Analyses of these
three and seven other individual LCMV-immune mice in-
fected with PV revealed that, although the level of the
NP205-specific T cell expansion widely varied (2–41-fold,
mean 
 
  
 
14.5 
 
 
 
 15, median 
 
  
 
6.9, 
 
n
 
 
 
 
 
 10) between indi-
vidual mice, all of the PV-infected LCMV-immune mice
unambiguously exhibited the same pattern of expansion of T
cells specific to this cross-reactive epitope.
However, in contrast with PV infection, challenge of
LCMV-immune mice with VV led to a much less predict-
able response, where T cells specific to different epitopes
were favored in different mice (Fig. 1 B). We summarized
the VV-induced changes in the hierarchies of LCMV-spe-
cific CD8 T cells in 26 examined mice in Table I. Several
distinctive features of heterologous immunity during VV in-
fection were noted. First, the increase in the number of pu-
tatively cross-reactive LCMV epitope–specific CD8 T cells
was less dramatic and more subtle than the expansion ob-
served during PV infection. In LCMV-immune mouse no.
11, although the frequencies of NP396-, GP33-, GP276-,
and GP118-specific CD8 T cells were dramatically and
somewhat comparably reduced, the frequency of NP205-
specific CD8 T cells remained about the same (Fig. 1 B,
105% of LCMV-immune mice). This maintenance of fre-
quency by the NP205-specific T cells actually represents an
increase in number, considering an overall increase in the
CD8 T cell percentage upon VV infection. In 26 LCMV-
immune control mice, the percentage of CD8 in the PBLs
was 10.1 
 
 
 
 2.3%, whereas the percentage of CD8 cells in
the VV-challenged LCMV-immune mice was 20.5 
 
 
 
 4.5%.
Furthermore, given the fact that the total numbers of leuko-
cytes were also routinely increased in the spleen after VV in-
fection (LCMV-immune 
 
 
 
 6.4 
 
 
 
 2.4 
 
 
 
 10
 
7
 
 vs. LCMV-
immune 
 
  
 
VV day 12 
 
 
 
 15 
 
 
 
 10
 
7
 
) and well reflected in
peripheral blood, the increase in number is expected to be
greater.
A second feature of these responses was that there was no
predictable increase of CD8 T cells specific to any particular
LCMV epitope, as the expansion pattern varied between in-
dividual mice (Fig. 1, B and C, and Table I). In mouse no.
12, the GP33/34-specific response (directed at either of two
overlapping epitopes) was most favored, and the 100% pres-
ervation of this GP33/34-specific response actually repre-
sents a 260% increase, taking into account the increased fre-
quency of CD8 T cells. Sometimes there was a response
directed against two epitopes, such as against NP205 and
GP118 in mouse no. 17. There were no obvious alterations
of T cell hierarchies in the individual LCMV-immune mice
that enabled us to predict what specificity would dominate
during the response to VV (Fig. 1 C).
A third important feature was that, despite the variable
and unpredictable nature of the responses of individual mice,
there were overall preferences in responses to some epitopes
over other epitopes. This can be seen in Table I, which
shows the percent recovery of the epitope-specific T cells
from 26 individual LCMV-immune mice before and after
VV infection. Given the increases in CD8 number in the
PBLs, we have highlighted the responses representing at least
1.5 times the day 0 value (Table I). It is clear that, although
the T cell responses in the individual mice behave differently
to VV, some epitopes, such as NP205, are much more likely
 
Table I.
 
Percent changes in LCMV-specific CD8 T cells 
upon VV infection
 
Mouse
no.
CD8
fold NP396 GP33 GP276 NP205 GP118
 
%%% %%
 
1 1.8 25 30 13 37 30
2 2.3 30 41 36 40 55
3 1.8 52 44 43
 
184
 
47
4 2.2 25 27 27 44 34
5 2.4 31 49 35
 
62
 
41
6 2.5
 
131
 
36 27 43 22
7 2.7 27 52 22
 
100 58
 
8 3.4 17 19 21 33 29
9 3.2 21 46 19 36 30
10 1.5 72 82 42 61 45
11 1.5 28 27 34
 
104
 
39
12 2.5 35
 
108
 
33
 
62
 
24
13 1.3 37 36 31 63 39
14 1.8 46 55 47 59 73
15 1.3 57 52 34 102 49
16 1.6 58 55 31
 
105
 
57
17 2.3 45 47 36
 
94 100
 
18 1.3 63 84 56 61 15
19 1.9 58 71 56 80 51
20 2.1 41
 
106
 
49
 
88
 
62
21 2.8 48
 
59
 
18 17
 
297
 
22 1.8
 
92
 
72
 
101
 
62 49
23 2.2 15 19 21
 
67
 
30
24 1.6 30 49 24
 
96
 
25
25 2.8 43
 
149
 
22
 
69
 
12
26 2.1 50 40 36
 
77
 
29
 
The percentage of LCMV epitope–specific CD8 T cells in 26 LCMV-immune individual 
mice before and after VV infection were determined via IFN-
 
 
 
 assay (Fig. 1 B), and the 
percent changes in those values are summarized. CD8 fold indicates the fold 
increases in the CD8 percentage after VV infection. The responses representing at 
least 1.5 times (considering the CD8 fold increase) the day 0 value are in bold. 
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to elicit a strong response than other epitopes, such as
GP276 or NP396. Analyzing these data in another way, we
asked which epitope generated the strongest relative re-
sponse in each mouse, and a nonrandom pattern evolved,
with a hierarchy of NP205 (50%) 
 
 
 
 GP33/34(23%) 
 
 
 
GP118 (15%) 
 
 
 
 NP396 (4%) 
 
  
 
GP276 (4%).
An example of the kinetics of the host response to VV in
LCMV-immune mice is given in Fig. 1 D, which shows a
mouse with a preferential NP205 response. Of note is that
the frequencies of total CD8 T cells and of T cells specific to
each LCMV epitope were reduced at day 4 after infection.
This is to be expected, as the level of protection against viral
replication during heterologous immunity is insufficient to
prevent the challenge virus from inducing cytokines that
cause across-the-board apoptosis and lymphopenia of mem-
ory T cells (21–23). By day 7, the percentage of NP205-spe-
cific T cells had increased from the day 4 time point, repre-
senting a marked increase in cell number from the day 0
time point, considering the substantial increase in the per-
cent of CD8 T cells overall. These increases were similarly
reflected at day 12, the chosen day for the previous assays.
The epitope-dependent increases in cell numbers sug-
gested that there was a variable epitope-dependent prolifera-
tion of LCMV-specific T cells induced by VV infection. To
confirm this, LCMV-immune donor spleen cells (Thy1.1)
were labeled with carboxyfluorescein diacetate-succinimidyl
ester (CFSE) and transferred into congenic Thy 1.2 recipi-
ents. These were infected with VV and assessed 6 d later for
epitope-specific increases in CD8 cell number and for cell
division, as assessed by loss in CFSE (more than seven divi-
sions). The results showed considerable variation in the spec-
ificity of the proliferating T cells between individual mice,
consistent with the results in Fig. 1 (not depicted).
 
VV-induced down-regulation of IL-7R
 
 
 
This trend toward epitope preference in an otherwise diffi-
cult-to-predict heterologous immune response was more
consistent with a TCR-based cross-reactivity phenomenon
than with a nonspecific TCR-independent bystander phe-
nomenon. As a technique to support the concept of a TCR-
mediated event, we examined the down-regulation of IL-7
receptors (IL-7R
 
 
 
) on CD8 T cells. Virus-specific CD8 T
cells in the memory phase express high levels of IL-7R
 
 
 
, but
these become down-regulated on TCR cross-linking. The
majority of LCMV-specific memory CD8 T cells are IL-
7R
 
 
 
hi
 
 (Fig. 2), but after secondary LCMV challenge in vivo,
 
 
 
50% of the LCMV-specific CD8 T cells of various speci-
ficities uniformly down-regulated IL-7R
 
 
 
 on their surface
(Fig. 2, top left quadrant). In contrast, LCMV-immune mice
challenged with PV down-regulated IL-7R
 
 
 
 only on the
highly cross-reactive NP205-specific T cells (unpublished
data). Interestingly, with a VV challenge, the pattern varied
between mice. IL-7R
 
 
 
 down-regulation was 23–42% in
some mice (nos. 1 and 2) on GP33/34-specific T cells, on
another mouse on GP118-specific T cells (no. 3), and on an-
other on NP205-specific T cells (no. 2) (Fig. 2, no. 2). All
other epitope-specific responses were 
 
 
 
12%, suggesting very
low, if any, TCR stimulation. VV-stimulated LCMV-spe-
cific T cells were examined for forward scatter, as an indica-
tor of cell size with regard to IL-7R
 
 
 
. The cells low in
IL-7R
 
 
 
 expression were larger, as indicated by substantially
increased forward scatter (e.g., GP33-specific CD8 T cells in
no. 2 mouse, FSC of IL-7R low 
 
  
 
402 vs. high 
 
 
 
 344).
These data are consistent with the concept that the T cells
are being stimulated through their TCR and, thus, probably
proliferating even though the epitope specificity varies be-
tween mice.
 
LCMV-immune CD8 T cells from a single donor exhibit 
remarkably similar VV-induced responses among 
several recipient hosts
 
We questioned whether the differences in VV-induced ex-
pansion of putatively cross-reactive T cells among different
LCMV-immune mice were a reflection, not of the antigenic
specificity of the LCMV-specific repertoire, but instead of
the distinct T cells used to generate that specificity. We had
reported previously that individual LCMV-infected mice
used different TCR repertoires to mount their virus-specific
Figure 2. Selective down-regulation of IL-7R  on LCMV-specific 
memory CD8 T cells on LCMV or VV infection. The levels of IL-7R  ex-
pression on LCMV epitope–specific memory CD8 T cells, visualized via IFN-  
assay, were examined in LCMV-immune mice or LCMV-immune mice in-
fected with homologous high dose (5   106 PFU) clone 13 strain of LCMV 
or heterologous VV 6 d after infection. The percentages above the top left 
quadrant of dot plots represent the proportion of the IL-7R low subset out 
of the total epitope-specific CD8 T cells. Outlined boxes indicate the 
epitope-specific CD8 T cells, in which  20% of the subset show down-
regulation of IL-7R . Representative data are shown for 3 out of 10 VV-
infected LCMV-immune mice. 
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T cell responses (16) and confirmed here that the V
 
 
 
8.1
CDR3 spectratypes of MHC dimer-sorted LCMV NP396-
specific and GP33-41–specific T cells varied between mice,
as reported elsewhere by us and others (references 24, 25 and
unpublished data). Because of the prevalence of VV-induced
NP205-specific responses in the present work, we examined
the TCR repertoire of MHC-tetramer–sorted NP205-spe-
cific CD8 T cells in LCMV-infected mice. Our results
showed, by PCR amplification, a dominant V
 
 
 
16 response
and weaker V
 
 
 
5 and V
 
 
 
8.2 responses, which varied be-
tween mice. Sequencing of a total of 37 NP205-specific
V
 
 
 
16 clones derived from three mice showed one V
 
 
 
clonotype common to all three mice, but all others
were unique to the individual mouse, indicating significant
mouse-to-mouse variation in TCRs specific for this epitope,
as expected (unpublished data).
This variation in epitope-specific TCR usage reveals a
private TCR repertoire that we hypothesized might provide
a basis for variability in the VV-induced T cell cross-reactiv-
ity against LCMV peptides. However, the data did not rule
out the possibility that the VV-induced response in LCMV-
immune mice was randomly stochastic and not reflective of
distinct patterns of cross-reactive T cells. To address this is-
sue, we designed a modified adoptive transfer system, in
Figure 3. LCMV-immune CD8 T cells from a single donor exhibit 
remarkably similar VV-induced responses among several recipient 
hosts. (A) CFSE-labeled LCMV-immune donor cells derived from a single 
donor were transferred into multiple hosts, which were infected with VV. 
(B) Donor-derived LCMV epitope–specific CD8 T cells were visualized in 
multiple recipient mice infected with VV (day 6). Two representative exper-
iments are shown out of 17 individual donor-recipients pairs (Table II).
 
Table II.
 
Selective proliferation of LCMV-specific CD8 T cells 
on VV infection in multiple transfer system
 
NP396
GP33/
GP34 GP276 NP205 GP118
 
A1
 
     
 
A2
 
     
 
A3
 
     
 
B1
 
     
 
B2
 
     
 
B3
 
     
 
C1
 
     
 
C2
 
     
 
C3
 
     
 
D1
 
     
 
D2
 
     
 
D3
 
     
 
E1
 
     
 
E2
 
     
 
E3
 
     
 
F1
 
     
 
F2
 
     
 
F3
 
     
 
G1
 
     
 
G2
 
     
 
H1
 
     
 
H2
 
     
I1      
I2      
J1      
J2      
K1      
K2      
L1      
L2      
M1      
M2      
N1      
N2      
O1      
O2      
P1      
P2      
R1      
R2      
CFSE-labeled splenocytes from individual LCMV-immune donor mice (A, B, and C) 
were adoptively transferred into two or three recipient mice (1, 2, and 3) that were 
then infected with VV (Fig. 3 A). Donor-derived LCMV epitope–specific CD8 T cells 
were visualized via IFN-  assay (Fig. 3 B).  , situations in which  50% of the 
epitope-specific T cells lack the CSFE label.JEM VOL. 201, February 21, 2005 529
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which the randomness in the heterologous T cell response
could be addressed. CFSE-labeled LCMV-immune donor
cells derived from a single donor were transferred into multi-
ple hosts, which were infected with VV (Fig. 3 A). We rea-
soned that if the secondary response on VV challenge was
random, variable epitope patterns would be observed among
the different recipients of LCMV-immune cells derived
from the same donor. If the putatively cross-reactive
epitope-specific expansions were similar between recipients,
this would argue against randomness and would strengthen
the argument that the unique, or private, epitope-specific
repertoire of the donor determines the pattern of heterolo-
gous immunity.
The results showed that multiple recipients of donor cells
from an individual LCMV-immune donor mouse generated
nearly identical epitope-specific responses on VV infection (Fig.
3 B). Among recipients receiving cells from LCMV-immune
donor A, GP33/34-specific CD8 T cells were preferentially ex-
panded. In contrast, preferential expansion was observed in
both GP33/34 and NP205-specific CD8 T cells among all the
recipients of cells from LCMV-immune donor B.
All the experiments in this regard are summarized in Ta-
ble II, where the “ ” designates situations where  50% of
the epitope-specific T cells lack the CSFE label (Table II). In
nearly every case, all the recipient mice from an individual
donor had similar expansions of epitope-specific T cells, but
the patterns differed from donor to donor. In some cases,
there were no responses to any of the tested epitopes. Table
II also reinforces the data from Table I showing that T cell
responses to NP205 and to GP33/34 are the most frequent.
These data indicate that the random stochastic process gen-
erating the primary LCMV-specific T cell response from
very low frequency epitope-specific naive T cell precursors
is less of a factor when the heterologous virus stimulates pu-
tative cross-reactive T cells from a much higher frequency of
memory T cells, which presumably get distributed in suffi-
cient frequencies between recipient mice. This also indicates
that the patterns of heterologous T cell responses are not
random but instead are predetermined by the individual pri-
vate specificities of the T cell repertoire.
Variations in response to a VV-encoded epitope cross-reactive 
with LCMV-specific T cells
The VV-induced expansions in LCMV epitope–specific T
cells predict that there may be cross-reactive epitopes be-
tween VV and LCMV, and the high incidence of expansion
of T cells specific to the NP205 epitope suggests that VV
may encode epitopes cross-reactive with NP205. We have
identified several VV-encoded amino acid sequences harbor-
ing Kb binding motifs and partial homology with NP205
(unpublished data). One VV-encoded epitope, generated
from VV protein A11R (198–205), has 4/8 amino acids in
common with NP205 and 3/8 amino acids in common with
GP34-41 and GP118. Subpopulations of T cells specific to
the A11R198 epitope cross-react with GP34 and GP118
and, to a lesser extent, with NP205. As an example, Fig. 4 A
presents CD8 T cells from an VV A11R198 peptide-stimu-
lated cell line derived from an LCMV-immune mouse and
shows that a subpopulation of them costain with tetramers
charged with A11R198 and GP118 peptides. A11R is de-
tected by a low percentage of T cells from LCMV-immune
mice (mean   0.33%   0.1, n   9) and to a lesser extent in
VV acutely infected (day 6) mice (mean   0.23%   0.19,
n   17). The frequency of A11R 198–specific CD8 T cells
was on average significantly higher (mean   0.55%   0.59,
n   29) after a day 6 VV infection of LCMV-immune mice
(P    0.03), but was highly variable, suggesting a private
specificity phenomenon.
To systematically address this issue, we examined the fate
of A11R 198–specific CD8 T cells before and after heterol-
ogous virus infection using a PBL longitudinal analysis, as in
Fig. 1. Fig. 4 B shows that low levels (0.2–0.5%) of A11R
198–specific CD8 T cells were present in LCMV-immune
PBLs. However, upon VV infection (day 12), only some of
the LCMV-immune mice (mouse nos. 4, 7, 10, 12, 13, and
19) showed significant expansions of T cells specific to the
cross-reactive VV epitope, whereas others did not (mouse
nos. 1, 2, 3, and 10 others not depicted; Fig. 4 B). Alto-
gether, longitudinal analysis experiments revealed that 6 out
of 19 LCMV-immune mice challenged with VV made rela-
tively strong ( 1.5% of CD8 T cells) responses to the A11R
198 peptide. In these experiments, four of the A11R 298 re-
sponders (mouse nos. 4, 7, 10, and 13) also responded to the
GP33/34 epitope, three (mouse nos. 10, 12, and 19) re-
sponded to the NP205 epitope, and one (mouse no. 12) re-
sponded to the GP118 epitope (unpublished data).
Proliferation and private specificities of LCMV-immune
donor-derived A11R 198–specific CD8 T cells upon VV in-
fection were confirmed via adoptive transfer experiments
with CFSE-labeled cells (Fig. 4 C). Here, the day 6 response
to A11R 198 is compared with the nearly always poor
GP276 response. Donors A and C gave rise to a proliferative
A11R 198 response in each of their recipients, whereas Do-
nor B gave rise to no A11R response in either recipient.
This documents the private specificities in challenge virus-
encoded epitope-specific T cell responses that can be engen-
dered as a consequence of heterologous immunity to a pre-
viously encountered virus.
DISCUSSION
Here, we have documented that a host’s unique private
specificities of its viral epitope-specific memory T cell popu-
lation can determine the cross-reactivity patterns to subse-
quent heterologous virus infections. It shows that these
unique private specificities, rather than being meaningless
immunological curiosities, impact the recognition of cross-
reactive antigens encoded by other pathogens and, as a con-
sequence, have the potential to alter the pathogenesis of a vi-
ral infection in a manner that is unique to the individual.
This work was initially based on the puzzling observation
that, unlike LCMV-infected mice challenged with PV,
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T cell response predictably dominates, VV infection of
LCMV-immune mice elicits a more subtle and less predict-
able expansion of LCMV epitope–specific CD8 T cells (3,
4). Here, we used sensitive measures to analyze these less
predictable responses and have revealed new insights into the
complexities of T cell dynamics during virus infections. Lon-
gitudinal analyses of LCMV-immune mice before and after
VV infection revealed that, although many of the LCMV-
specific memory cells were profoundly reduced in fre-
quency, others, presumably cross-reactive T cells specific to
distinct epitopes, were either maintained or increased in fre-
quency (Fig. 1). Attrition of noncross-reactive CD8 T cells
after VV infection probably resulted from cytokine-induced
bystander apoptosis of memory cells, shown to occur during
viral infections (21–23). Fig. 1 D shows that cells of all spec-
ificities decline at day 4 after infection and T cells specific to
only some, presumably cross-reactive, peptides thereafter in-
crease in number. Of note is that there was considerable
variation between mice regarding what group of epitope-
specific T cells was stimulated by VV. This mouse-to-mouse
variation in epitope selectivity was also seen in measure-
ments of the down-regulation of IL-7R , an indicator of re-
cent TCR stimulation (Fig. 2) and in loss of CSFE label
studies, an indicator of T cell proliferation (Fig. 3).
Despite the unpredictability in responses between indi-
viduals, there were some patterns, in that the major epitope-
specific responses occurred more often with some epitopes
(NP205, GP33/34, GP118) than with other epitopes
(NP396, GP276; Tables I and II). Our recent studies have
shown much higher frequencies (e.g.,  10%) of LCMV
epitope–specific T cells in the peritoneal cavity site of VV
inoculation, but with the same variability as that shown here
with peripheral blood and speen (unpublished data). A VV-
encoded peptide with sequence similarity to NP205, GP118,
and GP34-41 and with demonstrated cross-reactivity to each
of those epitopes detected a higher proportion of cells in
VV-challenged LCMV-immune mice, but its frequencies
also varied greatly between mice.
We believe that the differences in these VV-induced
LCMV epitope–specific T cell responses are due to the pri-
vate specificities of the TCR repertoire generated in individ-
ual mice to the different epitopes. The T cell repertoire is
Figure 4. Variations in response to a VV-encoded epitope cross-
reactive with LCMV-specific T cells. (A) MHC tetramer staining of cells 
from an A11R 198-stimulated T cell culture derived from an LCMV-immune 
mouse. Sample is costained with Kb tetramers charged with either the 
A11R198 or the GP118 peptide. (B) The frequencies of VV-derived A11R 
198 epitope-specific CD8 T cells were followed via IFN-  assay in the 
peripheral blood of individual LCMV-immune mice before (D0) and after 
(D12) VV infection. Representative data are shown for 9 out of 19 VV-
infected LCMV-immune mice. (C) Adoptive transfer experiments showing 
private specificities of A11R 198 responses. Splenocytes from LCMV-
immune mice were labeled with CFSE and transferred from one donor into 
two recipients. A11R 198- and GP276-specific responses were monitored 
6 d later, as in Fig. 3 B.JEM VOL. 201, February 21, 2005 531
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generated via random rearrangements of separate V, (D),
and J gene segments of TCR   and   chains, by imprecise
joining and random addition of nucleotides during this pro-
cess, and by the pairing of TCR   and   chains. The math-
ematically predicted potential T cell diversity (1015) is far
greater than the estimate of actual diversity (2   108) ob-
served in mice, in part because of the limits on the total
numbers of T cells (26, 27). This gap between potential and
actual diversity allows for different TCR repertoires in ge-
netically identical hosts, and experiments have shown very
little overlap of naive TCR repertoires between mice (14).
Upon immunization or infection, each host generates an
antigen-specific T cell response with the best available T
cell clones that randomly encounter epitope-expressing
APCs. Even if each host appears to elicit comparable T cell
responses with predictable immunodominance hierarchies
and V  usage (public specificity), there lies considerable
variation (private specificity) in clonal composition among
the same epitope-specific T cells between individual mice
(12–15).
The hierarchy of T cell responses specific to the various
LCMV epitopes is remarkably similar between mice im-
mune only to LCMV (Fig. 1), but the TCR usage varies be-
tween mice and between epitope-specific T cell responses
(16, 24, 25). Because the NP205 response was frequently
stimulated in VV-infected LCMV-immune mice, we ana-
lyzed the TCR repertoire of MHC-tetramer–sorted NP205-
specific T cells and, as expected, found considerable hetero-
geneity between mice. It might be anticipated that challenge
with a cross-reactive heterologous virus might amplify only a
subset of the T cells specific to a given epitope of a previ-
ously encountered virus, resulting in a less diverse T cell re-
sponse. We have not clarified that in the LCMV plus VV
system, where the cross-reactivity is unpredictable, but we
have studied this in PV-immune mice challenged with
LCMV, which invokes a strong cross-reactive NP205 re-
sponse. Our analyses have shown greatly diminished recep-
tor diversity of the responding T cells (unpublished data),
suggesting that limited receptor TCR diversity may be an
indicator of a cross-reactive response.
Despite the mouse-to-mouse variation in epitope prefer-
ences after VV infection, clear patterns of epitope preference
remained, with NP205   GP33/34   GP118   NP396  
GP276 (Table I). It is not clear why certain epitope-specific
CD8 T cells are more frequently cross-reactive than others,
although here the NP205, GP118, and GP34-41 epitopes
are Kb restricted, whereas the weakly stimulating NP396 and
GP276 epitopes are Db restricted. It is possible that VV en-
codes more Kb-restricted peptides that are potentially cross-
reactive than Db-restricted ones. The VV-encoded A11R
198 epitope is an example of such a cross-reactive epitope,
whose response differed greatly between one VV-challenged
LCMV-immune mouse and another. Another possibility is
that the three-dimensional structures of some peptides (such
as GP34-41 and NP205) are better at selecting a wider vari-
ety of T cell clones than others and, therefore, these epitope-
specific CD8 T cells could be more promiscuous in their in-
teractions with other peptides.
Nevertheless, the variation in TCR usage between indi-
viduals provides an opportunity for them to have remarkable
diversity in their T cell cross-reactivities with diverse patho-
gens. The demonstration that a memory pool from a single
donor could be transferred into three recipients that devel-
oped the same epitope-specific T cell response on challenge
with VV strongly indicates that it was the unique character-
istics (private specificities) of the memory pool that deter-
mined the nature of the response and not some random
stimulation event on VV challenge that would cause differ-
ent hosts to differ. Therefore, the stochastic events leading
to diversity in a primary immune response seem less of a
variable when generating a heterologous immune response
from the expanded clones of potentially cross-reactive mem-
ory cells.
The diversity of VV-induced LCMV epitope–specific
responses in LCMV-immune mice suggest that there may be
many potential epitopes that could be recognized by T cells
cross-reactive between the two viruses. VV encodes  200
proteins, probably encompassing  1,000 peptides that could
fit into the Kb or Db MHC binding motifs. Most of those
peptides would not normally be major players in the devel-
opment of a VV-specific immunodominant T cell repertoire
in naive mice. However, their expression on APCs may be
sufficient to stimulate cross-reactive LCMV epitope–specific
memory cells that are present at much higher frequencies
than any naive T cell. Here, we provided information re-
garding the frequent yet still unpredictable enhancement of
A11R 198–specific T cells in VV-challenged LCMV-immune
mice (Fig. 4, B and C).
The significance of this work is in the understanding of
the basic concepts of heterologous immunity. The replica-
tion of VV is reduced in LCMV-immune mice in compari-
son to naive mice, and T cell–dependent immunopathology
is more dramatic. Adoptive transfer studies have shown that
both the protective immunity and the immunopathology are
dependent on T cells and on IFN-  production (1). It is
noteworthy that IFN-  can be detected in vivo in different
proportions of T cells of each tested LCMV epitope specific-
ity (NP396, GP33, GP34, and NP205) by 3 d after infec-
tion, when viral titers are being controlled (3). It is not clear
whether this IFN-  production is a consequence of T cell
cross-reactivity or a nonspecific cytokine effect (28, 29). As
the infection progresses, T cells of distinct LCMV-epitope
specificities expand. Given the pervasive nature of T cell
cross-reactivity and the fact that it takes a stronger TCR sig-
nal to stimulate proliferation than IFN-  production (30), all
of these events could be determined by cross-reactivity, but
this is in need of further study.
This work also holds potentially significant clinical impli-
cations. Studies have revealed that prior immunity to LCMV
can result in acute necrosis of fat tissue after VV infection, al-
though the severity varies between individual mice (1). Ery-
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sociated with similar pathology in fat tissue. It is interesting
that erythema nodosum occurs sporadically in humans dur-
ing some viral infections and after vaccination for small pox
(31). This would suggest that an individual’s private T cell
repertoire, influenced by the history of infections, may con-
tribute to the development and variability of pathologies
during infectious diseases.
MATERIALS AND METHODS
Viruses. LCMV, strain Armstrong, and its highly disseminating variant,
clone 13, are ambisense RNA viruses in the arenavirus family and were
propagated in BHK21 baby hamster kidney cells (32, 33). VV, strain WR, a
DNA virus in the poxvirus family, was propagated in NCTC 929 cells (32).
PV, strain AN3739, a New World arenavirus only distantly related to
LCMV, was propagated in BHK21 cells (33).
Adoptive transfer of LCMV-immune splenocytes. Male C57BL/6
(B6) and B6.PL Thy1a/Cy (Thy1.1 ) mice were purchased from The Jack-
son Laboratory at 4–5 wk of age and maintained under specific pathogen-
free conditions within the Department of Animal Medicine at the Univer-
sity of Massachusetts Medical School. Thy1.1  mice infected i.p. with 5  
104 PFU of the Armstrong strain of LCMV (34) were considered LCMV
immune after  6 wk of infection. 2–4   107 CFSE-labeled LCMV-
immune Thy1.1  splenocytes were adoptively transferred via the tail vein
into Thy1.2  B6 mice in a 200- l volume of HBBS (GIBCO BRL; refer-
ence 4). All experiments were performed in compliance with institutional
guidelines as approved by the Institutional Animal Care and Use Commit-
tee of the University of Massachusetts Medical School.
CFSE labeling. Leukocytes from donor mice were harvested and isolated
as described previously (1). The donor leukocytes were labeled with CFSE
using a modification of previously described techniques (35, 36). In brief,
the splenocytes were suspended in HBBS (GIBCO BRL) at 2.5   107
cells/ml and incubated in 2  M CFSE (Molecular Probes) solution for 15
min at 37 C. After incubation, donor cells were washed twice with HBSS.
Flow cytometry and intracellular IFN-  staining. Single cell lym-
phocyte suspensions were prepared from peripheral blood and spleens. The
erythrocytes were lysed using a 0.84% NH4Cl solution. LCMV peptide–
specific, IFN- –secreting CD8  T cells were detected using the Cytofix/
Cytoperm Kit Plus (with GolgiPlug; BD Biosciences) as described previ-
ously (37). In brief, cells were incubated with 5  M of synthetic peptide, 10
U/ml of human recombinant IL-2 (BD Biosciences), and 0.2  l GolgiPlug
for 5 h at 37 C. After preincubation with 1  l of Fc block (2.4 G2) in 96-
well plates containing 100  l of FACS buffer (HBBS, 2% FCS, 0.1%
NaN3), the cells were stained for 30 min at 4 C with combinations of fluo-
rescently labeled mAbs specific for IL-7R (CD127, A7R34 biotin), CD44
(IM7, FITC), CD8  (53–6.7 per CP) and, after cells were permeabilized
with Cytofix/Cytoperm, stained with mAb to IFN-  (XMG1.2, allophy-
cocyanin), all purchased from BD Biosciences except for Ab specific for IL-
7R , which was purchased from eBioscience. For the staining of donor
cells in adoptive transfer experiments, mAb specific for Thy1.1 (OX-7, PE)
was additionally included. Freshly stained samples were analyzed using a
Becton Dickinson FACSCalibur and CELLQuest software.
Synthetic peptides. Several previously defined T cell epitopes encoded
by LCMV were used in this study (38, 39). LCMV-specific epitopes include
NP396-404 (FQPQNGQFI), GP33-41 (KAVYNFATC), GP276-286
(SGVENPGGYCL), NP205-212 (YTVKYPNL), and GP118-125 (ISHN-
FCNL). We identified one VV-specific Kb-restricted epitope from VV pro-
tein A11R 198–205 (AIVNYANL). Synthetic peptides listed here were
purchased from American Peptide and were purified with reverse phase–
HPLC to 90% purity.
CDR3 length spectratyping analysis and sequencing. CDR3 length
“spectratype” analysis was performed as described previously with modifica-
tion (16, 40). RNA samples were isolated from 5,000–60,000 MHC dimer- or
MHC-tetramer–sorted epitope-specific CD8 T cells or from an NP205-
specific cell line derived from an LCMV-immune mouse. For NP396-404–
and GP33-41–specific cells, RNA samples were amplified with primers for
C  and for V 8.1, using a GeneAmp RNA kit (PerkinElmer). The PCR
products were subjected to five cycles of runoff reaction with six fluorophore-
labeled J  primers (J  1.1, 1.2, 1.3, 1.4, 1.5, and 2.1). The runoff products
were mixed with gel-loading buffer (five parts of 100% formamide and one
part of 2.5% blue dextran/50  M EDTA), loaded onto a 4.75% acrylamide
sequencing gel, and analyzed on an automated DNA sequencer using Gene-
Scan software (Applied Biosystems). For NP205-specific T cells, TCR V 
analysis was performed by a qualitative PCR with specific primers for V 
1–18. The dominant V 16 PCR products were subcloned and sequenced
across the CDR3 region according to the method of Naumov et al. (11).
Dual tetramer staining of T cell culture. 107 splenocytes from
LCMV-immune mice were cocultured with VV A11R 198 peptide-pulsed
106 RMA-S cells in RPMI 1640 supplemented with 100 U/ml penicillin G,
100  g/ml streptomycin sulfate, 2  M L-glutamine, 10  M Hepes, 1  M
sodium pyruvate, 0.1  M MEM nonessential amino acids, 0.05  M
 -mercaptoethanol, and 10% FBS for 5 d at 37 C at 5% CO2. The IL-2
culture supplement BD T-Stim (BD Biosciences) was added after 5 d of
culture. After 10 d of stimulation, T cell lines were analyzed by tetramer
staining. Cells were incubated in FACS buffer with streptavidin and Fc
block to prevent nonspecific binding, washed, and stained with phycoeryth-
rin- and/or allophycocyanin-labeled tetramers for 60 min. After 40 min of
tetramer incubation, PerCP anti–mouse CD8  was added. Thereafter, cells
were washed twice with FACS buffer and fixed in Cytofix (BD Bio-
sciences). All staining was performed on ice. Samples were analyzed with
FlowJo software (Tree Star, Inc.). MHC class I Kb tetramers specific for VV
A11R 198 and LCMV GP118 were generated as described previously (41).
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